{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:39:28Z","timestamp":1775623168991,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470787"],"award-info":[{"award-number":["82470787"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470787"],"award-info":[{"award-number":["82470787"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical key specialty of the whole army","award":["51561Z24B4"],"award-info":[{"award-number":["51561Z24B4"]}]},{"name":"Clinical key specialty of the whole army","award":["51561Z24B4"],"award-info":[{"award-number":["51561Z24B4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-025-05778-3","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:48:43Z","timestamp":1748231323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Telitacicept for lupus nephritis with BAFF and APRIL double positivity in children: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Yang","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Hongwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Xiaopeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"10441","key":"5778_CR1","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326\u201338.","journal-title":"Lancet"},{"issue":"1","key":"5778_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"5778_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","volume":"23","author":"VC Trindade","year":"2021","unstructured":"Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of Childhood-Onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331\u201347.","journal-title":"Paediatr Drugs"},{"issue":"10","key":"5778_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/1744666X.2017.1366855","volume":"13","author":"M Cassia","year":"2017","unstructured":"Cassia M, Alberici F, Gallieni M, Jayne D. Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 2017;13(10):951\u201362.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"5778_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","volume":"27","author":"PR Harvey","year":"2013","unstructured":"Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs. 2013;27(2):85\u201395.","journal-title":"BioDrugs"},{"key":"5778_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","volume":"71","author":"R Cornelis","year":"2021","unstructured":"Cornelis R, Chang HD, Radbruch A. Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol. 2021;71:97\u2013102.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"5778_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;56(8):948\u201359.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"5778_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/1744666X.2023.2145281","volume":"19","author":"E Krustev","year":"2023","unstructured":"Krustev E, Clarke AE, Barber M. B cell depletion and Inhibition in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(1):55\u201370.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"5778_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","volume":"7","author":"J Chan","year":"2023","unstructured":"Chan J, Walters GD, Puri P, Jiang SH. Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol. 2023;7(1):37.","journal-title":"BMC Rheumatol"},{"issue":"2S Suppl 1","key":"5778_CR10","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/TP.0000000000001729","volume":"102","author":"M Ma","year":"2018","unstructured":"Ma M, Yung S, Chan TM. mTOR Inhibition and kidney diseases. Transplantation. 2018;102(2S Suppl 1):S32\u201340.","journal-title":"Transplantation"},{"issue":"2","key":"5778_CR11","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, et al. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. 2023;10(2):e001074.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"5778_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2023;32(1):94\u2013100.","journal-title":"Lupus"},{"issue":"4","key":"5778_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/etm.2024.12660","volume":"28","author":"H Zhu","year":"2024","unstructured":"Zhu H, Hu HQ, Wei HL, et al. Efficacy and safety of telitacicept in patients with lupus nephritis. Exp Ther Med. 2024;28(4):371.","journal-title":"Exp Ther Med"},{"issue":"12","key":"5778_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3899\/jrheum.180507","volume":"45","author":"D Yap","year":"2018","unstructured":"Yap D, Tang C, Chan G, et al. Longterm data on sirolimus treatment in patients with lupus nephritis. J Rheumatol. 2018;45(12):1663\u201370.","journal-title":"J Rheumatol"},{"issue":"5","key":"5778_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.semarthrit.2020.07.006","volume":"50","author":"L Ji","year":"2020","unstructured":"Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(5):1073\u201380.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5778_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022;31(8):998\u20131006.","journal-title":"Lupus"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05778-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:48:44Z","timestamp":1748231324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05778-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5778"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05778-3","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fast review by the Ethics Committee of the First Affiliated Hospital of the PLA Army Military Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent of patient and guardian. In the case of a patient using a specific treatment, such as Taitacept, when we sign a consent form, the patient and legal guardian agree that the data may be used for medical research and will not affect the course of treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors agreed to publish the manuscript. The patient\u2019s father signed a written informed consent for publication and uploaded supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}